Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Peripheral venous disease? 501 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 501 reports of Peripheral venous disease have been filed in association with MEPOLIZUMAB (Nucala). This represents 1.2% of all adverse event reports for MEPOLIZUMAB.

501
Reports of Peripheral venous disease with MEPOLIZUMAB
1.2%
of all MEPOLIZUMAB reports
498
Deaths
414
Hospitalizations

How Dangerous Is Peripheral venous disease From MEPOLIZUMAB?

Of the 501 reports, 498 (99.4%) resulted in death, 414 (82.6%) required hospitalization, and 425 (84.8%) were considered life-threatening.

Is Peripheral venous disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 501 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Peripheral venous disease?

RITUXIMAB (1,281) ADALIMUMAB (1,249) METHOTREXATE (1,246) SECUKINUMAB (1,186) ABATACEPT (1,168) DICLOFENAC (1,168) LEFLUNOMIDE (1,154) TOCILIZUMAB (1,137) PREDNISONE (1,101) ALENDRONATE (1,097)

Which MEPOLIZUMAB Alternatives Have Lower Peripheral venous disease Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Peripheral venous disease Reports All Drugs Causing Peripheral venous disease MEPOLIZUMAB Demographics